NCT06922370 The Osteoarticular Manifestations in Patients With Gitelman Syndrome
| NCT ID | NCT06922370 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Second Affiliated Hospital, Zhejiang University, School of Medicine |
| Condition | Gitelman Syndrome |
| Study Type | OBSERVATIONAL |
| Enrollment | 120 participants |
| Start Date | 2021-11-01 |
| Primary Completion | 2025-11-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 120 participants in total. It began in 2021-11-01 with a primary completion date of 2025-11-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Patients with clinically and genetically confirmed Gitelman Syndrome are screened for CPPD, and the clinical and radiographic manifestations are collected and analyzed.
Eligibility Criteria
Inclusion Criteria: * Patients confirmed with Gitelman Syndrome Exclusion Criteria: * Patients with other confounding situations such as Bartter Syndrome, hyperparathyroidism
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06922370 clinical trial?
This trial is open to participants of all sexes, studying Gitelman Syndrome. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06922370 currently recruiting?
Yes, NCT06922370 is actively recruiting participants. Contact the research team at moulj511@zju.edu.cn for enrollment information.
Where is the NCT06922370 trial being conducted?
This trial is being conducted at Hangzhou, China.
Who is sponsoring the NCT06922370 clinical trial?
NCT06922370 is sponsored by Second Affiliated Hospital, Zhejiang University, School of Medicine. The trial plans to enroll 120 participants.